Sequencing of Stereotactic Ablative Body Radiation Therapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

Official Title

Sequencing of Stereotactic Ablative Body Radiation Therapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

Summary:

This investigator driven Phase Ib study will examine the safety, efficacy and biological effects of two schedules of pembrolizumab, an antibody targeted against anti-programmed cell death 1 (PD-1), which will be given either before or after stereotactic ablative body radiation therapy (SABR) for metastatic NSCLC.

Trial Description

Primary Outcome:

  • Adverse events measured using CTCAE version 4.03
Secondary Outcome:
  • Overall response assessed using RECIST 1.1
  • Overall response assessed using irRECIST
  • Overall response assessed using PERCIST1.0
  • Overall response assessed using Peter Mac Metabolic Response Criteria
  • Overall survival
  • Progression free survival (PFS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society